Drs Jacob Sands and Julia Rotow discuss the latest breakthroughs in lung cancer treatment, including targeted therapy options, toxicities, and diagnostic technology.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/999027). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Young Adults and Lung Cancer: Testing and Treatment Options for a Population That Does Not Qualify for Screening https://www.medscape.com/viewarticle/984258

EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/34127383/

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/29151359/

Osimertinib With/Without Platinum-Based Chemotherapy as First-Line Treatment in Patients With EGFRm Advanced NSCLC (FLAURA2). 2023 World Conference on Lung Cancer. Abstract PL03.13. https://www.sciencedirect.com/science/article/abs/pii/S1556086423008110

MARIPOSA: Phase 3 Study of First-Line Amivantamab + Lazertinib Versus Osimertinib in EGFR-Mutant Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/34911336/

Discovery of Amivantamab (JNJ-61186372), a Bispecific Antibody Targeting EGFR and MET https://pubmed.ncbi.nlm.nih.gov/33839159/

Amivantamab Plus Chemotherapy With and Without Lazertinib in EGFR-Mutant Advanced NSCLC After Disease Progression on Osimertinib: Primary Results From the Phase III MARIPOSA-2 Study https://pubmed.ncbi.nlm.nih.gov/37879444/

Consensus Recommendations for Optimizing Biomarker Testing to Identify and Treat Advanced EGFR-Mutated Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/33380864/

Next Generation Sequencing Technology in Lung Cancer Diagnosis https://pubmed.ncbi.nlm.nih.gov/34571741/

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer https://pubmed.ncbi.nlm.nih.gov/32955177/

Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress https://pubmed.ncbi.nlm.nih.gov/33558193/

[NCT03456076] A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer. https://clinicaltrials.gov/study/NCT03456076

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies https://pubmed.ncbi.nlm.nih.gov/33172113/

Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/NEJMoa2302299

NCCN Guidelines: Non-Small Cell Lung Cancer https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450

Amivantamab Plus Chemotherapy in NSCLC With EGFR Exon 20 Insertions https://pubmed.ncbi.nlm.nih.gov/37870976/